Glaukos Corporation (GKOS)

NYQ – Real vaqt narxi. Valyuta: USD

144.42

+1.85 (1.30%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

141.62

-2.80 (-1.94%)

Bozordan keyin: Jun 26, 2026, 5:05 PM EDT

05.06.2026

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.

12.05.2026

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

30.04.2026

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.

30.04.2026

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

30.04.2026

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

29.04.2026

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

29.04.2026

Glaukos Announces First Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.

Videolar

No Data

There is no data to display

Press-relizlar

29.04.2026

Glaukos Announces First Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.

16.04.2026

Glaukos Announces the Release of its 2025 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. “I am prou.

15.04.2026

Glaukos Receives Permanent J-code for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease.

19.03.2026

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Glaukos Corporation (GKOS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Glaukos Corporation (GKOS)

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Search stocks

Glaukos Corporation (GKOS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Glaukos Corporation (GKOS)

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos Announces First Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Glaukos Announces First Quarter 2026 Financial Results

Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Receives Permanent J-code for Epioxa™

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care